Fiche centre
Northeast Regional Epilepsy Group
Hackensack — United States
Essais liés9clinical trials
VilleHackensacklocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT03635073
Essais cliniques associés
9| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| TAK-935 | Épilepsie | Phase 1/2 | NCT03166215 | Study of TAK-935 as an Adjunctive Therapy in Participants With Developmental and/or Epileptic Encephalopathies | COMPLETED |
| TAK-935 | Épilepsie | Phase 2 | NCT03650452 | ELEKTRA — A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Participants With Developmental and/or Epileptic Encephalopathies | COMPLETED |
| Soticlestat | Épilepsie | Phase 2 | NCT03635073 | Endymion 1 — A Study of Soticlestat in Adults and Children With Rare Epilepsies | TERMINATED |
| AAV9-hSyn1-miGRIK2 | Épilepsie | Phase 1/2 | NCT06063850 | GenTLE — AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy | RECRUITING |
| ABS-1230 | Épilepsie | Phase 2 | NCT07600736 | KYRON — A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of ABS-1230 in Pediatric and Young Adult Participants With KCNT1-related Epilepsy | RECRUITING |
| XEN1101 | Épilepsie | Phase 3 | NCT05667142 | X-ACKT — A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures | RECRUITING |
| Clemizole HCl | Épilepsie | Phase 3 | NCT04462770 | ARGUS — A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome | RECRUITING |
| Xcopri | Épilepsie | Phase 3 | NCT05067634 | Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures | ACTIVE_NOT_RECRUITING |
| RAP-219 | Épilepsie | Phase 3 | NCT07563881 | FOCUS 1 — Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1 | RECRUITING |